JP2001526218A - Ｇｌｃ１ａ緑内障の治療のための３−ベンゾイル−フェニル酢酸、エステル、またはアミドの使用 - Google Patents
Ｇｌｃ１ａ緑内障の治療のための３−ベンゾイル−フェニル酢酸、エステル、またはアミドの使用Info
- Publication number
- JP2001526218A JP2001526218A JP2000525095A JP2000525095A JP2001526218A JP 2001526218 A JP2001526218 A JP 2001526218A JP 2000525095 A JP2000525095 A JP 2000525095A JP 2000525095 A JP2000525095 A JP 2000525095A JP 2001526218 A JP2001526218 A JP 2001526218A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- glaucoma
- branched alkyl
- glc1a
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100029839 Myocilin Human genes 0.000 title claims abstract description 12
- 101000585663 Homo sapiens Myocilin Proteins 0.000 title claims abstract 4
- 208000010412 Glaucoma Diseases 0.000 title claims description 33
- ALDSXDRDRWDASQ-UHFFFAOYSA-N 2-(3-benzoylphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ALDSXDRDRWDASQ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title description 3
- 150000002148 esters Chemical class 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 125000003107 substituted aryl group Chemical group 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 17
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 description 26
- 210000001585 trabecular meshwork Anatomy 0.000 description 19
- 238000012937 correction Methods 0.000 description 18
- 230000004410 intraocular pressure Effects 0.000 description 13
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 10
- 230000003637 steroidlike Effects 0.000 description 10
- 239000003862 glucocorticoid Substances 0.000 description 9
- 206010012565 Developmental glaucoma Diseases 0.000 description 8
- 208000028507 juvenile open angle glaucoma Diseases 0.000 description 8
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 201000006336 Juvenile glaucoma Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229960001002 nepafenac Drugs 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 206010018325 Congenital glaucomas Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001742 aqueous humor Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 201000006366 primary open angle glaucoma Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 3
- 101710196550 Myocilin Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 210000002159 anterior chamber Anatomy 0.000 description 3
- 230000004406 elevated intraocular pressure Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- XAARRDGAECXQPW-UHFFFAOYSA-N 2-[2-amino-3-(4-fluorobenzoyl)phenyl]acetamide Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC(F)=CC=2)=C1N XAARRDGAECXQPW-UHFFFAOYSA-N 0.000 description 2
- 101150018198 COX1 gene Proteins 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101150043980 COXI gene Proteins 0.000 description 2
- 101150086475 COXII gene Proteins 0.000 description 2
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 2
- 102100027456 Cytochrome c oxidase subunit 2 Human genes 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 208000007157 Hydrophthalmos Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 101150079116 MT-CO1 gene Proteins 0.000 description 2
- 101150021539 MT-CO2 gene Proteins 0.000 description 2
- -1 amide derivative of 3-benzoylphenylacetic acid Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 201000001024 buphthalmos Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 201000006672 primary congenital glaucoma Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QYWOBAQCODTFCM-UHFFFAOYSA-N 2-[2-amino-3-(4-chlorobenzoyl)phenyl]acetamide Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC(Cl)=CC=2)=C1N QYWOBAQCODTFCM-UHFFFAOYSA-N 0.000 description 1
- VOUHFMUNVVHZNG-UHFFFAOYSA-N 2-amino-2-[3-(4-chlorobenzoyl)phenyl]acetamide Chemical compound NC(=O)C(N)C1=CC=CC(C(=O)C=2C=CC(Cl)=CC=2)=C1 VOUHFMUNVVHZNG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- RAPBNVDSDCTNRC-UHFFFAOYSA-N Chlorobenzilate Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)OCC)C1=CC=C(Cl)C=C1 RAPBNVDSDCTNRC-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 208000033137 Pediatric-onset glaucoma of genetic origin Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000016047 hereditary glaucoma Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 108010048477 olfactomedin Proteins 0.000 description 1
- 208000033298 open angle B glaucoma 1 Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 201000000041 pigment dispersion syndrome Diseases 0.000 description 1
- 208000032288 primary infantile B glaucoma 3 Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/994,903 US6066671A (en) | 1997-12-19 | 1997-12-19 | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| US08/994,903 | 1997-12-19 | ||
| PCT/US1998/025744 WO1999032104A1 (en) | 1997-12-19 | 1998-12-04 | Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glc1a glaucoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001526218A true JP2001526218A (ja) | 2001-12-18 |
| JP2001526218A5 JP2001526218A5 (https=) | 2006-03-30 |
Family
ID=25541199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000525095A Pending JP2001526218A (ja) | 1997-12-19 | 1998-12-04 | Ｇｌｃ１ａ緑内障の治療のための３−ベンゾイル−フェニル酢酸、エステル、またはアミドの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6066671A (https=) |
| EP (1) | EP1039895B1 (https=) |
| JP (1) | JP2001526218A (https=) |
| AT (1) | ATE218336T1 (https=) |
| AU (1) | AU746075C (https=) |
| BR (1) | BR9813767A (https=) |
| CA (1) | CA2313386A1 (https=) |
| DE (1) | DE69805846T2 (https=) |
| DK (1) | DK1039895T3 (https=) |
| ES (1) | ES2178291T3 (https=) |
| PT (1) | PT1039895E (https=) |
| WO (1) | WO1999032104A1 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004520267A (ja) * | 2000-08-14 | 2004-07-08 | アルコン，インコーポレイテッド | ベンゾイルフェニル酢酸を使用して、血管形成関連障害を処置するための方法 |
| JP2007501799A (ja) * | 2003-08-07 | 2007-02-01 | アラーガン、インコーポレイテッド | 眼内に医薬を送達するための組成物ならびにその調製方法および使用方法 |
| JP2008521926A (ja) * | 2004-12-02 | 2008-06-26 | アルコン，インコーポレイテッド | 局所用ネパフェナク処方物 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138511B1 (en) | 1997-01-28 | 2006-11-21 | The Regents Of The University Of California | Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders |
| US6475724B1 (en) * | 1997-01-28 | 2002-11-05 | The Regents Of The University Of California | Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders |
| US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| US7943162B2 (en) | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| ATE283013T1 (de) | 1999-10-21 | 2004-12-15 | Alcon Inc | Medikamentenzuführvorrichtung |
| AR030346A1 (es) | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
| DE60214697T2 (de) | 2001-07-23 | 2007-09-13 | Alcon Inc. | Vorrichtung zur freisetzung eines ophthalmischen arzneimittels |
| DE60217679T2 (de) | 2001-07-23 | 2007-10-25 | Alcon Inc. | Vorrichtung zur freisetzung eines ophthalmischen arzneimittels |
| US20040132773A1 (en) * | 2001-08-13 | 2004-07-08 | Gamache Daniel A | Method of treating neurodgenerative disorders of the retina and optic nerve head |
| US20030119000A1 (en) * | 2001-11-05 | 2003-06-26 | Jon Polansky | Methods to screen and treat individuals with glaucoma or the propensity to develop glaucoma |
| BR0309747A (pt) * | 2002-05-03 | 2005-04-26 | Alcon Inc | Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial |
| US6864282B2 (en) | 2002-08-05 | 2005-03-08 | Allergan, Inc. | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| PT1586316E (pt) * | 2003-01-21 | 2008-05-28 | Senju Pharma Co | Preparação líquida aquosa contendo ácido 2-amino-3-(4- bromobenzoil)fenilacético |
| AR043161A1 (es) * | 2003-02-14 | 2005-07-20 | Sucampo Pharmaceuticals Inc | Composicion oftalmica para tratar hipertension ocular y glaucoma |
| US20030187072A1 (en) * | 2003-02-14 | 2003-10-02 | Kapin Michael A. | Method of treating angiogenesis-related disorders |
| DE602004023106D1 (de) * | 2003-11-07 | 2009-10-22 | Senju Pharma Co | Pharmazeutische zusammensetzung mit prostaglandin |
| DE602004017477D1 (de) * | 2004-11-09 | 2008-12-11 | Novagali Pharma Sa | Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential |
| PT2026651E (pt) * | 2006-03-08 | 2013-06-04 | Cortria Corp | Terapia combinada com inibidores cox não selectivos para prevenir lesões gástricas relacionadas com a cox |
| US20090105245A1 (en) * | 2006-12-21 | 2009-04-23 | Bingaman David P | Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor |
| US20080153818A1 (en) * | 2006-12-21 | 2008-06-26 | Bingaman David P | Methods for preventing inflammation during surgery |
| WO2008080110A1 (en) * | 2006-12-21 | 2008-07-03 | Alcon, Inc. | Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor |
| US20100292289A1 (en) * | 2007-11-30 | 2010-11-18 | Ampla Pharmaceuticals Inc. | Treatment of metabolic syndrome with novel amides |
| EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
| US8227451B2 (en) * | 2008-11-12 | 2012-07-24 | Auspex Pharmaceuticals | Phenylacetic acid inhibitors of cyclooxygenase |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
| EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA805476B (en) * | 1979-09-26 | 1981-11-25 | Robins Co Inc A H | 2-amino-3-benzoyl-phenylacetamides and cyclic homologues |
| US4683242A (en) * | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
| US5151444B1 (en) | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US5565492A (en) | 1988-07-18 | 1996-10-15 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| DE1300150T1 (de) | 1988-09-06 | 2003-09-18 | Pharmacia Ab, Stockholm | Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck |
| US5093329A (en) | 1990-03-12 | 1992-03-03 | Allergan, Inc. | Intraocular pressure reducing prostaglandin-like 7-oxabicyclo derivatives |
| US5270049A (en) | 1990-11-09 | 1993-12-14 | Allergan, Inc. | 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives |
| US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5627209A (en) | 1993-12-15 | 1997-05-06 | Alcon Laboratories, Inc. | Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension |
| US5721273A (en) | 1993-12-15 | 1998-02-24 | Alcon Laboratories, Inc. | Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension |
| US5474985A (en) | 1993-12-22 | 1995-12-12 | The Regents Of The University Of California | Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors |
| US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US5698733A (en) | 1994-09-30 | 1997-12-16 | Alcon Laboratories, Inc. | Use of 9-deoxy prostaglandin derivatives to treat glaucoma |
| WO1996011003A1 (en) * | 1994-10-10 | 1996-04-18 | Novartis Ag | Ophthalmic and aural compositions containing diclofenac potassium |
| US5606043A (en) * | 1994-11-03 | 1997-02-25 | The Regents Of The University Of California | Methods for the diagnosis of glaucoma |
| US5607966A (en) | 1994-12-23 | 1997-03-04 | Alcon Laboratories, Inc. | Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory prodrugs |
| US5925673A (en) | 1994-12-23 | 1999-07-20 | Alcon Laboratories, Inc. | Benzofurans and benzopyrans as cytoprotective agents |
| AU7672096A (en) * | 1995-06-07 | 1998-06-03 | Alcon Laboratories, Inc. | Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy |
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
| US5599535A (en) | 1995-06-07 | 1997-02-04 | Regents Of The University Of California | Methods for the cyto-protection of the trabecular meshwork |
| US5750564A (en) | 1995-09-12 | 1998-05-12 | Hellberg; Mark | Anti-oxidant esters of non-steroidal anti-inflammatory agents |
| US5814660A (en) | 1995-12-22 | 1998-09-29 | Alcon Laboratories, Inc. | 9-oxa prostaglandin analogs as ocular hypotensives |
| WO1997023223A1 (en) | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
| US5866602A (en) | 1995-12-22 | 1999-02-02 | Alcon Laboratories, Inc. | Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
| EP0968183A2 (en) * | 1997-03-07 | 2000-01-05 | Alcon Laboratories, Inc. | 13-thia prostaglandins for use in glaucoma therapy |
| US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| SE9803761D0 (sv) | 1998-11-04 | 1998-11-04 | Synphora Ab | Method to avoid increased iridial pigmentation during prostaglandin treatment |
-
1997
- 1997-12-19 US US08/994,903 patent/US6066671A/en not_active Expired - Lifetime
-
1998
- 1998-12-04 EP EP98960732A patent/EP1039895B1/en not_active Expired - Lifetime
- 1998-12-04 AT AT98960732T patent/ATE218336T1/de not_active IP Right Cessation
- 1998-12-04 AU AU16259/99A patent/AU746075C/en not_active Ceased
- 1998-12-04 CA CA002313386A patent/CA2313386A1/en not_active Abandoned
- 1998-12-04 WO PCT/US1998/025744 patent/WO1999032104A1/en not_active Ceased
- 1998-12-04 DK DK98960732T patent/DK1039895T3/da active
- 1998-12-04 DE DE69805846T patent/DE69805846T2/de not_active Expired - Fee Related
- 1998-12-04 PT PT98960732T patent/PT1039895E/pt unknown
- 1998-12-04 ES ES98960732T patent/ES2178291T3/es not_active Expired - Lifetime
- 1998-12-04 BR BR9813767-0A patent/BR9813767A/pt not_active Application Discontinuation
- 1998-12-04 JP JP2000525095A patent/JP2001526218A/ja active Pending
-
2000
- 2000-05-22 US US09/575,833 patent/US6342524B1/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004520267A (ja) * | 2000-08-14 | 2004-07-08 | アルコン，インコーポレイテッド | ベンゾイルフェニル酢酸を使用して、血管形成関連障害を処置するための方法 |
| JP2007501799A (ja) * | 2003-08-07 | 2007-02-01 | アラーガン、インコーポレイテッド | 眼内に医薬を送達するための組成物ならびにその調製方法および使用方法 |
| JP2008521926A (ja) * | 2004-12-02 | 2008-06-26 | アルコン，インコーポレイテッド | 局所用ネパフェナク処方物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US6066671A (en) | 2000-05-23 |
| BR9813767A (pt) | 2000-10-03 |
| AU746075C (en) | 2002-10-17 |
| CA2313386A1 (en) | 1999-07-01 |
| DK1039895T3 (da) | 2002-09-23 |
| WO1999032104A1 (en) | 1999-07-01 |
| US6342524B1 (en) | 2002-01-29 |
| PT1039895E (pt) | 2002-10-31 |
| EP1039895B1 (en) | 2002-06-05 |
| DE69805846D1 (de) | 2002-07-11 |
| HK1027748A1 (en) | 2001-01-23 |
| ES2178291T3 (es) | 2002-12-16 |
| DE69805846T2 (de) | 2003-01-16 |
| AU746075B2 (en) | 2002-04-11 |
| ATE218336T1 (de) | 2002-06-15 |
| AU1625999A (en) | 1999-07-12 |
| EP1039895A1 (en) | 2000-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001526218A (ja) | Ｇｌｃ１ａ緑内障の治療のための３−ベンゾイル−フェニル酢酸、エステル、またはアミドの使用 | |
| US6646001B2 (en) | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension | |
| AU695888B2 (en) | Use of non-steroidal cyclooxygenase inhibitors to treat elevated intraocular pressure | |
| EP2262476B1 (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops. | |
| JP4755599B2 (ja) | 緑内障性網膜症および視神経障害の処置のための薬剤 | |
| JP2011515494A (ja) | テトラサイクリンファミリー抗生物質を用いる、眼瞼縁および涙液膜機能の改善ならびに眼瞼縁疾患の処置のための方法 | |
| US20040213782A1 (en) | Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure | |
| EP0093380A2 (en) | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma | |
| MXPA06007062A (es) | Antagonistas cdk2 como antagonistas del factor de transcripcion c-maf de forma corta para el tratamiento de glaucoma. | |
| US6090798A (en) | Treatment of GLC1A glaucoma with glucocorticoid antagonists | |
| JP4758581B2 (ja) | 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用 | |
| US12048685B2 (en) | Transient receptor potential cation channel subfamily m member 8 (TRPM8) antagonists and methods of use | |
| JP2011518828A (ja) | 眼球障害の処置のためのｐａｉ−１の発現および活性インヒビター | |
| JP5087011B2 (ja) | 眼疾患モデル用非ヒト動物 | |
| HK1027748B (en) | Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glc1a glaucoma | |
| US20240269115A1 (en) | Pyrazolone compounds for use in degenerative retinal diseases | |
| US20240024348A1 (en) | Methods and compositions for the treatment of glaucoma and related conditions | |
| MXPA00005853A (en) | Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glc1a glaucoma | |
| CA2476908A1 (en) | Composition comprising an l-ascorbic acid and an organic base for treatment of ocular disorders | |
| US20240216370A1 (en) | Treatment of corneal vascularisation | |
| TW202529793A (zh) | 生長激素抑制劑的用途、和含有生長激素抑制劑的藥物組合物、製劑、及其裝置 | |
| HUT65880A (en) | Process for preparation of ophtalmological medicaments containing pyridine derivatives usefules for treatment of ocular hypertension | |
| Osude-Uzodike et al. | Comparative intraocular pressure reduction efficacy of latanoprost and timolol meleate in open angle glaucomaand ocular hypertensive patient | |
| JPWO1999043347A1 (ja) | 角膜上皮障害症治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060131 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090428 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100112 |